News | October 31, 2023
Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
RHTC will address a long-standing healthcare access issue for all the local population
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Investment is additive to KKR’s existing health care growth strategy
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
